TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive NCI Stands Firm On Assist “Downscaling” Despite 150 Letters From States, Volunteers January 15, 1993
TCL Archive In Brief: Friedell To Head McDowell Network, New Kentucky Cancer Center; Nine Expiring Core Grants Approved October 29, 1982
